Suzanne Dickson, Department of Physiology, Division of Endocrinology

Basuppgifter

Arbete

CV

Article - Review (4)

1. Control of growth hormone secretion at the single cell level.
   Mason W T, Dickson S L, Leng G.
   Acta Paediatr Suppl 1993:388:84-92; discussion 93.[Source: PubMed®]
   [Links: PMID: 8101112]
2. Growth hormone (GH) secretagogues and neuroendocrine regulation of GH secretion.
   Dickson S L, Bailey A R, Leng G.
   Growth Horm IGF Res. 1999:9:89-91.[Source: PubMed®]
   [Links: PMID: 10429889]
3. Effects of growth hormone and its secretagogues on bone.
   Svensson J, Lall S, Dickson S L, Bengtsson B A, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson J O.
   Endocrine 2001:14(1):63-6.[Source: PubMed®]
   [Links: PMID: 11322502 | DOI länk]
4. On the site and mechanism of action of the anti-obesity effects of interleukin-6.
   Jansson John-Olov, Wallenius Kristina, Wernstedt Ingrid, Ohlsson Claes, Dickson Suzanne L, Wallenius Ville.
   Growth Horm IGF Res. 2003:13:S28-32.[Source: PubMed®]
   [Links: PMID: 12914723]

Article - Peer reviewed scientific (57)

1. Growth hormone release evoked by electrical stimulation of the arcuate nucleus in anesthetized male rats.
   Dickson S L, Leng G, Robinson I C.
   Brain Res. 1993:623(1):95-100.[Source: PubMed®]
   [Links: PMID: 8221099]
2. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons.
   Dickson S L, Leng G, Robinson I C.
   Neuroscience 1993:53(2):303-6.[Source: PubMed®]
   [Links: PMID: 8492908]
3. Electrical stimulation of the rat periventricular nucleus influences the activity of hypothalamic arcuate neurones.
   Dickson S L, Leng G, Robinson I C.
   J Neuroendocrinol. 1994:6(4):359-67.[Source: PubMed®]
   [Links: PMID: 7987365]
4. GH-deficient dw/dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide-6.
   Dickson S L, Doutrelant-Viltart O, Leng G.
   J Endocrinol. 1995:146(3):519-26.[Source: PubMed®]
   [Links: PMID: 7595148]
5. Central actions of peptide and non-peptide growth hormone secretagogues in the rat.
   Dickson S L, Leng G, Dyball R E, Smith R G.
   Neuroendocrinology 1995:61(1):36-43.[Source: PubMed®]
   [Links: PMID: 7731496]
6. Retrogradely labelled neurosecretory neurones of the rat hypothalamic arcuate nucleus express Fos protein following systemic injection of GH-releasing peptide-6.
   Dickson S L, Doutrelant-Viltart O, Dyball R E, Leng G.
   J Endocrinol. 1996:151(2):323-31.[Source: PubMed®]
   [Links: PMID: 8958794]
7. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6.
   Dickson S L, Luckman S M.
   Endocrinology 1997:138(2):771-7.[Source: PubMed®]
   [Links: PMID: 9003014]
8. Attenuation of the growth hormone secretagogue induction of Fos protein in the rat arcuate nucleus by central somatostatin action.
   Dickson S L, Viltart O, Bailey A R, Leng G.
   Neuroendocrinology 1997:66(3):188-94.[Source: PubMed®]
   [Links: PMID: 9380276]
9. An electrophysiological and morphological investigation of the projections of growth hormone-releasing peptide-6-responsive neurons in the rat arcuate nucleus to the median eminence and to the paraventricular nucleus.
   Honda K, Bailey A R, Bull P M, Macdonald L P, Dickson S L, Leng G.
   Neuroscience 1999:90(3):875-83.[Source: PubMed®]
   [Links: PMID: 10218787]
10. Chronic central infusion of growth hormone secretagogues: effects on fos expression and peptide gene expression in the rat arcuate nucleus.
    Bailey A R, Giles M, Brown C H, Bull P M, Macdonald L P, Smith L C, Smith R G, Leng G, Dickson S L.
    Neuroendocrinology 1999:70(2):83-92.[Source: PubMed®]
    [Links: PMID: 10461022]
11. Activation of arcuate nucleus neurons by systemic administration of leptin and growth hormone-releasing peptide-6 in normal and fasted rats.
    Luckman S M, Rosenzweig I, Dickson S L.
    Neuroendocrinology 1999:70(2):93-100.[Source: PubMed®]
    [Links: PMID: 10461023]
12. GHRP-6-induced changes in electrical activity of single cells in the arcuate, ventromedial and periventricular nucleus neurones [correction of nuclei] of a hypothalamic slice preparation in vitro.
    Hewson A K, Viltart O, McKenzie D N, Dyball R E, Dickson S L.
    J Neuroendocrinol. 1999:11(12):919-23.[Source: PubMed®]
    [Links: PMID: 10583726]
13. Growth hormone secretagogue activation of the arcuate nucleus and brainstem occurs via a non-noradrenergic pathway.
    Bailey A R, Von Englehardt N, Leng G, Smith R G, Dickson S L.
    J Neuroendocrinol. 2000:12(3):191-7.[Source: PubMed®]
    [Links: PMID: 10718914]
14. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.
    Svensson J, Lall S, Dickson S L, Bengtsson B A, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson J O.
    J Endocrinol. 2000:165(3):569-77.[Source: PubMed®]
    [Links: PMID: 10828840]
15. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats.
    Hewson A K, Dickson S L.
    J Neuroendocrinol. 2000:12(11):1047-9.[Source: PubMed®]
    [Links: PMID: 11069119]
16. Differential effects of α-, β- and γ2-melanocyte-stimulating hormones on hypothalamic neuronal activation and feeding in the fasted rat.
    Milington GWM, Tung LYC, Hewson AK, ORahilly S, Dickson SL.
    Neuroscience 2001:108(3):437-45.[Source: User]
    [Links: DOI länk]
17. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.
    Lall S, Tung L Y, Ohlsson C, Jansson J O, Dickson S L.
    Biochem Biophys Res Commun. 2001:280(1):132-8.[Source: PubMed®]
    [Links: PMID: 11162489 | DOI länk]
18. Actions of leptin on growth hormone secretagogue-responsive neurones in the rat hypothalamic arcuate nucleus recorded in vitro.
    Tung Y C, Hewson A K, Dickson S L.
    J Neuroendocrinol. 2001:13(2):209-15.[Source: PubMed®]
    [Links: PMID: 11168847]
19. Intracerebroventricular injection of neuropeptide FF, an opioid modulating neuropeptide, acutely reduces food intake and stimulates water intake in the rat.
    Sunter D, Hewson A K, Lynam S, Dickson S L.
    Neurosci Lett. 2001:313(3):145-8.[Source: PubMed®]
    [Links: PMID: 11682148]
20. Interleukin-6-deficient mice develop mature-onset obesity.
    Wallenius Ville, Wallenius Kristina, Ahrén Bo, Rudling Mats, Carlsten Hans, Dickson Suzanne L, Ohlsson Claes, Jansson John-Olov.
    Nat Med. 2002:8(1):75-9.[Source: PubMed®]
    [Links: PMID: 11786910 | DOI länk]
21. Ghrelin: a newly discovered hormone.
    Dickson Suzanne L.
    J Neuroendocrinol. 2002:14(1):83-4.[Source: PubMed®]
    [Links: PMID: 11903816]
22. Intracerebroventricular interleukin-6 treatment decreases body fat in rats.
    Wallenius Kristina, Wallenius Ville, Sunter David, Dickson Suzanne L, Jansson John-Olov.
    Biochem Biophys Res Commun. 2002:293(1):560-5.[Source: PubMed®]
    [Links: PMID: 12054638 | DOI länk]
23. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection.
    Frago Laura M, Pañeda Covadonga, Dickson Suzanne L, Hewson Adrian K, Argente Jesús, Chowen Julie A.
    Endocrinology 2002:143(10):4113-22.[Source: PubMed®]
    [Links: PMID: 12239123]
24. The rat arcuate nucleus integrates peripheral signals provided by leptin, insulin, and a ghrelin mimetic.
    Hewson Adrian K, Tung Loraine Y C, Connell David W, Tookman Laura, Dickson Suzanne L.
    Diabetes 2002:51(12):3412-9.[Source: PubMed®]
    [Links: PMID: 12453894]
25. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse.
    Challis B G, Pinnock S B, Coll A P, Carter R N, Dickson S L, O'Rahilly S.
    Biochem Biophys Res Commun. 2003:311(4):915-9.[Source: PubMed®]
    [Links: PMID: 14623268]
26. Intracerebroventricular injection of apelin-13 reduces food intake in the rat.
    Sunter David, Hewson Adrian K, Dickson Suzanne L.
    Neurosci Lett. 2003:353(1):1-4.[Source: PubMed®]
    [Links: PMID: 14642423]
27. Plasma vasopressin concentrations and Fos protein expression in the supraoptic nucleus following osmotic stimulation or hypovolaemia in the ovariectomized rat: effect of oestradiol replacement.
    Hartley D E, Dickson S L, Forsling M L.
    J Neuroendocrinol. 2004:16(3):191-7.[Source: PubMed®]
    [Links: PMID: 15049849 | DOI länk]
28. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36).
    Challis B G, Coll A P, Yeo G S H, Pinnock S B, Dickson S L, Thresher R R, Dixon J, Zahn D, Rochford J J, White A, Oliver R L, Millington G, Aparicio S A, Colledge W H, Russ A P, Carlton M B, O'Rahilly S.
    Proc Natl Acad Sci U.S.A. 2004:101(13):4695-700.[Source: PubMed®]
    [Links: PMID: 15070780 | DOI länk]
29. Glucocorticoid-dependent stimulation of adiposity and appetite by a ghrelin mimetic in the rat.
    Tung Y L, Hewson A K, Dickson S L.
    Eur J Endocrinol. 2004:150(6):905-11.[Source: PubMed®]
    [Links: PMID: 15191362]
30. Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomised mice.
    Dornonville de la Cour C, Lindqvist A, Egecioglu E, Tung Y C L, Surve V, Ohlsson C, Jansson J-O, Erlanson-Albertsson C, Dickson S L, Håkanson R.
    Gut 2005:54(7):907-13.[Source: PubMed®]
    [Links: PMID: 15849166 | DOI länk]
31. Increased body fat in mice with a targeted mutation of the paternally expressed imprinted gene Peg3.
    Curley J P, Pinnock S B, Dickson S L, Thresher R, Miyoshi N, Surani M A, Keverne E B.
    FASEB J. 2005:19(10):1302-4.[Source: PubMed®]
    [Links: PMID: 15928196 | DOI länk]
32. Central responsiveness to a ghrelin mimetic (GHRP-6) is rapidly altered by acute changes in nutritional status in rats.
    Tung Y C L, Hewson A K, Carter R N, Dickson S L.
    J Neuroendocrinol. 2005:17(6):387-93.[Source: PubMed®]
    [Links: PMID: 15929744 | DOI länk]
33. Central administration of resistin promotes short-term satiety in rats.
    Tovar Sulay, Nogueiras Rubén, Tung Loraine Y C, Castañeda Tamara R, Vázquez María Jesús, Morris Amanda, Williams Lynda M, Dickson Suzanne L, Diéguez Carlos.
    Eur J Endocrinol. 2005:153(3):R1-5.[Source: PubMed®]
    [Links: PMID: 16131594 | DOI länk]
34. Growth hormone receptor deficiency results in blunted ghrelin feeding response, obesity, and hypolipidemia in mice.
    Egecioglu Emil, Bjursell Mikael, Ljungberg Anna, Dickson Suzanne L, Kopchick John J, Bergström Göran, Svensson Lennart, Oscarsson Jan, Törnell Jan, Bohlooly-Y Mohammad.
    Am J Physiol Endocrinol Metab. 2006:290(2):E317-25.[Source: PubMed®]
    [Links: PMID: 16174655 | DOI länk]
35. Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic systems in mice: implications for its involvement in brain reward.
    Jerlhag Elisabet, Egecioglu Emil, Dickson Suzanne L, Andersson Malin, Svensson Lennart, Engel Jörgen A.
    Addict Biol 2006:11(1):45-54.[Source: PubMed®]
    [Links: PMID: 16759336 | DOI länk]
36. Maternal stress alters endocrine function of the feto-placental unit in rats.
    Mairesse Jérôme, Lesage Jean, Breton Christophe, Bréant Bernadette, Hahn Tom, Darnaudéry Muriel, Dickson Suzanne L, Seckl Jonathan, Blondeau Bertrand, Vieau Didier, Maccari Stefania, Viltart Odile.
    Am J Physiol Endocrinol Metab. 2007:292(6):E1526-33.[Source: PubMed®]
    [Links: PMID: 17264224 | DOI länk]
37. Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens.
    Jerlhag Elisabet, Egecioglu Emil, Dickson Suzanne L, Douhan Annika, Svensson Lennart, Engel Jörgen A.
    Addict Biol 2007:12(1):6-16.[Source: PubMed®]
    [Links: PMID: 17407492 | DOI länk]
38. Hypothalamic gene expression following ghrelin therapy to gastrectomized rodents.
    Egecioglu Emil, Stenström Björn, Pinnock Scarlett B, Tung Loraine Y C, Dornonville de la Cour Charlotta, Lindqvist Andreas, Håkanson Rolf, Syversen Unni, Chen Duan, Dickson Suzanne L.
    Regul Pept. 2008:146(1):176-82.[Source: PubMed®]
    [Links: PMID: 17936372 | DOI länk]
39. Feeding behavior in rats subjected to gastrectomy or gastric bypass surgery.
    Furnes M W, Stenstrom B, Tømmerås K, Skoglund T, Dickson S L, Kulseng B, Zhao C-M, Chen D.
    Eur Surg Res 2008:40(3):279-88.[Source: PubMed®]
    [Links: PMID: 18253047 | DOI länk]
40. Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors are involved in mediating the ghrelin-induced locomotor stimulation and dopamine overflow in nucleus accumbens.
    Jerlhag Elisabet, Egecioglu Emil, Dickson Suzanne L, Svensson Lennart, Engel Jörgen A.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2008:18(7):508-18.[Source: PubMed®]
    [Links: PMID: 18343642 | DOI länk]
41. Anorexigenic and electrophysiological actions of novel ghrelin receptor (GHS-R1A) antagonists in rats.
    Salomé Nicolas, Haage David, Perrissoud Daniel, Moulin Aline, Demange Luc, Egecioglu Emil, Fehrentz Jean-Alain, Martinez Jean, Dickson Suzanne L.
    Eur J Pharmacol. 2009:612(1):167-73.[Source: PubMed®]
    [Links: PMID: 19356720 | DOI länk]
42. Interleukin-6 gene knockout influences energy balance regulating peptides in the hypothalamic paraventricular and supraoptic nuclei.
    Benrick A, Schéle E, Pinnock S B, Wernstedt-Asterholm I, Dickson S L, Karlsson-Lindahl L, Jansson J-O.
    J Neuroendocrinol. 2009:21(7):620-8.[Source: PubMed®]
    [Links: PMID: 19490366 | DOI länk]
43. Interleukin-6 gene knockout influences energy balance regulating peptides in the hypothalamic paraventricular and supraoptic nuclei.
    Benrick A, Schéle E, Pinnock S B, Wernstedt-Asterholm I, Dickson S L, Karlsson-Lindahl L, Jansson J-O.
    J Neuroendocrinol. 2009:21(7):620-8.[Source: PubMed®]
    [Links: PMID: 19490366 | DOI länk]
44. On the central mechanism underlying ghrelin's chronic pro-obesity effects in rats: new insights from studies exploiting a potent ghrelin receptor (GHS-R1A) antagonist.
    Salomé N, Hansson C, Taube M, Gustafsson-Ericson L, Egecioglu E, Karlsson-Lindahl L, Fehrentz J A, Martinez J, Perrissoud D, Dickson S L.
    J Neuroendocrinol. 2009[Source: PubMed®]
    [Links: PMID: 19523166 | DOI länk]
45. Requirement of central ghrelin signaling for alcohol reward.
    Jerlhag Elisabet, Egecioglu Emil, Landgren Sara, Salomé Nicolas, Heilig Markus, Moechars Diederik, Datta Rakesh, Perrissoud Daniel, Dickson Suzanne L, Engel Jörgen A.
    Proc Natl Acad Sci U.S.A. 2009:106(27):11318-23.[Source: PubMed®]
    [Links: PMID: 19564604 | DOI länk]
46. Central NMU signaling in body weight and energy balance regulation: evidence from NMUR2 deletion and chronic central NMU treatment in mice.
    Egecioglu Emil, Ploj Karolina, Xu Xiufeng, Bjursell Mikael, Salomé Nicolas, Andersson Niklas, Ohlsson Claes, Taube Magdalena, Hansson Caroline, Bohlooly-Y Mohammad, Morgan David G A, Dickson Suzanne L.
    Am J Physiol Endocrinol Metab. 2009:297(3):E708-16.[Source: PubMed®]
    [Links: PMID: 19584200 | DOI länk]
47. Ghrelin increases intake of rewarding food in rodents.
    Egecioglu Emil, Jerlhag Elisabet, Salomé Nicolas, Skibicka Karolina P, Haage David, Bohlooly-Y Mohammad, Andersson Daniel, Bjursell Mikael, Perrissoud Daniel, Engel Jörgen A, Dickson Suzanne L.
    Addict Biol 2010:15(3):304-11.[Source: PubMed®]
    [Links: PMID: 20477752 | DOI länk]
48. Ghrelin receptor antagonism attenuates cocaine- and amphetamine-induced locomotor stimulation, accumbal dopamine release, and conditioned place preference.
    Jerlhag Elisabet, Egecioglu Emil, Dickson Suzanne L, Engel Jörgen A.
    Psychopharmacology (Berl.) 2010:211(4):415-22.[Source: PubMed®]
    [Links: PMID: 20559820 | DOI länk]
49. Glutamatergic regulation of ghrelin-induced activation of the mesolimbic dopamine system.
    Jerlhag Elisabet, Egecioglu Emil, Dickson Suzanne L, Engel Jörgen A.
    Addiction biology 2010[Source: PubMed®]
    [Links: PMID: 20579004 | DOI länk]
50. Acute and chronic suppression of the central ghrelin signaling system reveals a role in food anticipatory activity.
    Verhagen Linda A W, Egecioglu Emil, Luijendijk Mieneke C M, Hillebrand Jacquelien J G, Adan Roger A H, Dickson Suzanne L.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2010[Source: PubMed®]
    [Links: PMID: 20620030 | DOI länk]
51. Blockade of central nicotine acetylcholine receptor signaling attenuate ghrelin-induced food intake in rodents.
    Dickson S L, Hrabovszky E, Hansson C, Jerlhag E, Alvarez-Crespo M, Skibicka K P, Molnar C S, Liposits Z, Engel J A, Egecioglu E.
    Neuroscience 2010:171(4):1180-6.[Source: PubMed®]
    [Links: PMID: 20933579 | DOI länk]
52. The alcohol-induced locomotor stimulation and accumbal dopamine release is suppressed in ghrelin knockout mice.
    Jerlhag Elisabet, Landgren Sara, Egecioglu Emil, Dickson Suzanne L, Engel Jörgen A.
    Alcohol (Fayetteville, N.Y.) 2010[Source: PubMed®]
    [Links: PMID: 21145690 | DOI länk]
53. Glutamatergic regulation of ghrelin-induced activation of the mesolimbic dopamine system.
    Jerlhag Elisabet, Egecioglu Emil, Dickson Suzanne L, Engel Jörgen A.
    Addict Biol 2011:16(1):82-91.[Source: PubMed®]
    [Links: PMID: 20579004 | DOI länk]
54. Acute and chronic suppression of the central ghrelin signaling system reveals a role in food anticipatory activity.
    Verhagen Linda A W, Egecioglu Emil, Luijendijk Mieneke C M, Hillebrand Jacquelien J G, Adan Roger A H, Dickson Suzanne L.
    Eur Neuropsychopharmacol 2011:21(5):384-92.[Source: PubMed®]
    [Links: PMID: 20620030 | DOI länk]
55. Central administration of ghrelin alters emotional responses in rats: behavioural, electrophysiological and molecular evidence.
    Hansson C, Haage D, Taube M, Egecioglu E, Salomé N, Dickson S L.
    Neuroscience 2011:180:201-11.[Source: PubMed®]
    [Links: PMID: 21303683 | DOI länk]
56. Role of ghrelin in food reward: impact of ghrelin on sucrose self-administration and mesolimbic dopamine and acetylcholine receptor gene expression.
    Skibicka Karolina P, Hansson Caroline, Egecioglu Emil, Dickson Suzanne L.
    Addiction biology 2011[Source: PubMed®]
    [Links: PMID: 21309956 | DOI länk]
57. The role of the central ghrelin system in reward from food and chemical drugs.
    Dickson Suzanne L, Egecioglu Emil, Landgren Sara, Skibicka Karolina P, Engel Jörgen A, Jerlhag Elisabet.
    Molecular and cellular endocrinology 2011[Source: PubMed®]
    [Links: PMID: 21354264 | DOI länk]

Book Chapter (6)

1. Neurochemical identification of cells expressing c-fos mRNA in the rat arcuate nucleus following systemic growth hormone-releasing peptide-6 injection.
   Dickson Suzanne L, Luckman SM.
   Growth hormone secretagogues. Springer; 1996, ISBN 9780387947075. [Source: User]
2. Electrophysiological studies of the arcuate nucleus: central actions of growth hormone secretagogues.
   Leng G, Bailey ART, Dickson Suzanna L, Smith RG.
   Growth hormone secretagogues. M. Dekker; 1998, pp 173-86. ISBN 9780824798321. [Source: User]
3. Neuroendocrine control of growth hormone secretion.
   Jansson John-Olov, Dickson Suzanne L.
   Growth hormone. Springer; 1999, pp 3-16. ISBN 9780792384786. [Source: User]
   [Links: Google Books]
4. Hypothalamic site and mechanism of action of growth hormone secretagogues.
   Dickson Suzanna L.
   Growth hormone secretagogues: basic findings and clinical implications. Elsevier; 1999, pp 79-90. ISBN 9780444829337. [Source: User]
5. Central actions of peptide and non-peptide growth hormone secretagogues.
   Dickson Suzanna L, Leng G.
   Human growth hormone : research and clinical practice. Totowa, New Jersey, USA: Humana; 2000, pp 85-95. ISBN 0-89603-505-0. [Source: User]
6. Interactions of growth hormone secretagogues with leptin-sensitive brain networks.
   Dickson Suzanna L, Tung LYC LYC, Lall S, Jansson J-O, Hewson AK.
   Brain somatic cross-talk and the central control of metabolism. Springer; 2003, pp 1-14. ISBN 9783540000907. [Source: User]
   [Links: Google Books]

1984-1988 University of Edinburgh, UK. BSc (Honours) in Pharmacology.
1989-1993 University of Cambridge. PhD (Cantab) in Neuroendocrinology. Neural control of growth hormone secretion. Supervisor: Professor Gareth Leng at the Babraham Institute.

Arbetsgivare	Anställningsgrad		Började	Slutade
Övrigt Show info 1993-1994 The Babraham Institute, Cambridge, UK. Higher Scientific Officer. Central actions of growth hormone secretagogues. Supervisor: Prof Gareth Leng. Sponsor: Merck Inc, Rahway, New Jersey, USA		100%	1993	1994
Övrigt Show info 1994-1996 King’s College London, UK. Lecturer in Anatomy		100%	1994	1996
Övrigt Show info 1996-2004 University of Cambridge. Lecturer then Senior Lecturer in Physiology. 1996-2004 Fellow of Peterhouse, Cambridge.		100%	1996	2004
Landsting - Västra Götalandsregionen - Specialiserad vård - Sahlgrenska Universitetssjukhuset, Område 6 - Medicin Sahlgrenska Show info 1999-2001 Visiting Professor, Dept Internal Medicine, Sahlgrenska University Hospital.		100%	1999	2001
Statligt - Universitet - Göteborgs universitet - Sahlgrenska akademin - Institutionen för klinisk neurovetenskap [1991 - 2005] Show info 2004 - Professor of Physiology/Neuroendocrinology, The Sahlgrenska Academy at the University of Gothenburg.		100%	2004	2005
Statligt - Universitet - Göteborgs universitet - Sahlgrenska akademin - Institutionen för neurovetenskap och fysiologi [2006 - ] Show info 2004 - Professor of Physiology/Neuroendocrinology, The Sahlgrenska Academy at the University of Gothenburg.		100%	2006

University of Gothenburg (May 2004-)

• Molecular Cell Biology II and Endocrinology for Medical Students: 10 Lectures on Endocrinology and Metabolism.
• Apotekarprogrammet och Biovetenskapliga Läkemedelsprogrammet. Three lectures on obesity, 4 lectures on glucose homeostasis, 2 introduction to hormone. 5th semester (third year students).
• Nutrition students: 1 lecture on obesity.
• Physiolotherapy: 3 lectures on obesity and energy balance
• Dental students: 2 lectures on appetite.
• Elective in Metabolism: 2 lectures on future obesity therpy.
• Examining was also part of the teaching activities.

University of Cambridge (1990-1994 and 1996).

• 1B physiology/anatomy: Senior Examiner 2000-2001, Examiner 1996-2001. Supervision of second year Medical, Veterinary & Natural Science Undergraduate students (Tripos 1B) in Neurophysiology, Reproductive Physiology and Endocrinology.
• Formal lectures in Part II (final year): Control of the pituitary (2 lectures). Body composition (2 lectures).
• Part II (Final Year). Course organiser for Clinical topics in Physiology.
• Formal lectures: Part Ia (Year 1 Medical Students): Control of body composition (4 lectures; 2000-2003); Part 1b (Year 2, Natural Science): Nutrition and control of body weight (3 lectures, 2001-2003); Part 1a (Year 2, Natural Science Students); Digestive system (7 lectures, 1996-2003); Demonstrator for practical classes in Neuroanatomy, Neuroendocrinology and several 1a and 1b practicals (1996-2003); Part II (final year medical and science students) Control of the pituitary (2 lectures), Body composition (2 lectures; 1997-2003).

King's College London (1994-1996).

• Lecturing to undergraduate Medical, Human Biology and Science students: Endocrinology and Reproduction (2nd Year), Neuroendocrinology (3rd year), Special Topics in Human Biology (3rd Year), Advanced Neuroanatomy (3rd Year).
• Demonstrator in Neuroanatomy.

Professional Affiliations and Activities:

• Member of the Editorial Board for Neuroendocrinology (1997-)
• Member of the Editorial Board for the Endocrinology Domain of TheScientificWorldJOURNAL (2005-)
• Member of the Physiological Society (1993-), British Neuroendocrine Group (1990-), Endocrine Society (1991-), Growth Hormone Research Society (1993-), European Neuroendocrine Society (1999-).
• Referee of manuscripts for several journals: Neuroendocrinology, J Endocrinology, J Neuroendocrinology and Endocrinology.
• Examination of 6 PhD theses for the University of Cambridge, The University of London. and the University of Uppsala (Opponent)

Research grants
Current Research Grants

• EC 7th Framework Grant “NeuroFAST” (2009-2114). I am the Coordinator (Project Head) of this Integrated Project. (6 M€ over 5 years, of which 850,000 € is dedicated to research in my group).
• EC7th Framework grant "Full4Health" (2011-2015). I am one of 12 Partners, coordinated fro Aberdeen, investigating gut-brain signalling in energy balance regulation. I receive 350,000 € over 5 years.
• EC 7th Framework grant “EuroCHIP” (2009-2113). I am one of 7 Partners, coordinated from Cambridge, investigating gut-brain signalling in energy balance regulation. I receive 380,000 € over 4 years.
• Swedish Medical Research Council (2010-2012). Mechanisms underlying ghrelin’s effects on appetite, reward and mood. 600,000 SEK per year for 3 years.
• ALF Gothenburg. 1 M SEK over 2 years (Ends 2010).
• SSF Grant to the Sahlgrenska Center for Metabolism and Cardiovascular Research. This grant is coordinated by Prof Jan Boren and I am one of 11 Partners. 45 M SEK from which I received funding for one post-doctoral scientist for 3 years.

Former Research Grants

• Swedish Medical Research Council (2007-2009). Novel central actions of ghrelin. (1,650,000 SEK).
• EC 6th Framework (2004-2008). I was the Coordinator (Project Head) of this Integrated Project. Novel drug targets for obesity and type 2 diabetes (“DIABESITY”). 27 European Partners including 4 small companies. Largest EC grant awarded in the area of chronic disease (with the exception of cancer). www.eurodiabesity.org (€11,700,000 = 110,570,000 SEK).
• ALF Gothenburg. (2006-2008) The role of stomach-derived ghrelin in the regulation of fat mass (1.65 M SEK).
• Novo Nordisk Fonden (2007). Impact of ghrelin on the CNS pathways regulating energy balance and reward-seeking behaviour. (187,500 SEK).
• Medical Research Council, UK (1995). Site and mechanism of action of growth hormone secretagogues. (£65,000 = 885,000SEK)
• Start-up grants from the Royal Society, Physiological Society and European Science Foundation (1995). I was the principal investigator on all of these. (£20,000 = 275,000 SEK)
• MRC Project grant (1995-1998). Neural control of growth hormone secretion. Principal investigator. (£164,000 = 2,230,000SEK)
• Novo Nordisk grant (1997-2000). Long term actions of growth hormone secretagogues. Principal investigator. £95,000 = 1,292,000 SEK)
• Pfizer Inc, USA (1998-1999). Interactions of growth hormone secretagogues with the hypothalamic circuits controlling body weight. Principal investigator. (£168,800 = 2,296,000 SEK)
• MRC Career Establishment Grant (1999-2004). Hypothalamic circuits controlling body weight. Principal investigator. 5 years. I also won a competitive Prize for ~£45,000 for equipment. (£378,900 = 5,154,000 SEK).
• Swedish Foundation for International Co-operative Research (1999-2000). 2 year grant. Long term studies of growth hormone secretagogues. Principal investigator. (340,000 SEK).
• European Commission 5th Framework grant (2000-2003). Growth hormone secretagogues in aging. I was Coordinator of this grant that had 5 European partners, including one company (NovoNordisk A/S, Copenhagen). The grant was rated number 1 out of 211 applications. (€1,018,000 = 9,620,000 SEK).
• Wellcome Trust Integrative Animal and Human Physiology (2001-2006). The Cambridge/ Oxford Integrative Physiology Consortium for the Study of Common Metabolic Disease. I am a co-applicant on this grant co-ordinated by Professor Steve O’Rahilly, Cambridge University. (£5 million = 68,016,000 SEK).
• British Heart Foundation (2002-2005). Programming of appetite by nutrition in early life. Co-applicant with Prof N Hales, Cambridge University. £138,990 = 1,891,000 SEK).
• Swedish Medical Research Council (2003-2006). Cross-talk between peripheral tissues and the hypothalamus for the control of appetite, body weight and metabolism. (1,100,000 SEK).
• Novo Nordisk Fonden (2005). Central actions of the adipokines resistin and adiponectin (125,000 SEK).
• Novo Nordisk Fonden (2006). Effect of total ghrelin knockout or gastrectomy on expression of hypothalamic genes involved in energy balance. (187,500 SEK).

Current Research Group
5 post-doctoral researchers: Emil Egecioglu, David Haage, Karolina Skibicka, Mayte Alverez, Anders Friberg
PhD Students: Caroline Hansson.

Former Research Group
Supervisor for PhD student: Ms Sabrina Lall “Long and short term regulation of body composition by growth hormone secretagogues”. Thesis awarded 2000.
Supervisor for PhD student. Ms Loraine Tung, “Control of energy balance by circulating factors”. Thesis awarded 2002.
Supervisor for first Swedish PhD student at Gothenburg Gothenburg (Emil Ecegioglu). Role of ghrelin in energy balance and reward. Awarded 2007.
Co-PhD supervisor for 2 PhDs: George Millington (awarded 2005), David Hartley (awarded 2005)
Post-doctoral research assistants in Cambridge (Dr Adrian K. Hewson, Dr David Sunter, Dr Scarlett Pinnock, Dr Loraine Tung)
Post-doctoral researchers in Gothenburg. Nicolas Salome, Lisa Gustafsson, Emilia Rung, Linda Karlsson-Lindahl, Magdalena Taube

Research Seminars and Oral Communications
Invited Speaker at Congresses
1994 Serono Symposium on Growth Hormone-Releasing Peptides (Florida). Title: Evidence for a Central Site of Action of GHRP-6.
1997 Serono Symosium on Growth Hormone-Releasing Peptides (Florida). Title: Neurochemical identification of the cells in the rat hypothalamic arcuate nucleus expressing c-fos mRNA following injection of GHRP-6.
1997 European Conference for Brain Research (France). Title: Central actions of peptide and non-peptide growth hormone secretagogues. Sponsored by Europeptides.
1998 26th International Symposium, GH and Growth Factors in Endocrinology and Metabolism, Palma de Mallorca. Central effects of GH secretagogues. Sponsored by Pharmacia-Upjohn.
1999-2002 Swedish Post-graduate Course in Endocrinology, Marstrand.
1999 Novo Nordisk Norditropin Launch Symposium, Copenhagen.
2000 Third International Symposium on growth hormone secretagogues (Colorado, USA). Title: GHS and leptin.
2002 Foundation Ipsen: Brain somatic cross-talk and the control of metabolism (Paris). Title: Interactions of GH secretagogues with leptin-sensitive circuits.
2002 International Congress of Neuroendocrinology, Bristol. Title: Ghrelin: interactions with hypothalamic circuits controlling energy balance.
2002 Italian Society of Neuroscience, Como. Title: Ghrelin interacts with central obesity circuits.
2004 5th International GHS Symposium, Protofino, Italy.
2004 International Symposium on Growth Hormone, Santiago de Compostela. Spain
2006 First International Workshop on Animal Models of Weight Loss Surgery, Boston, USA
2007 Drug development for Obesity. Controlling appetite through circulating hormones: Ghrelin London, UK.
2009 Swiss Winter Ingestion Conference
2009 8th Dutch Endo-Neuro-Psycho meeting, Doorwerth. Ghrelin, a gut-brain signal influencing appetite, body weight and reward.
2009 International Symposium on Ghrelin. The central ghrelin signalling system in alcohol reward, food reward and mood. Keynote lecture.
2010 Gothia Forums mötesplats för kliniska forskare.
2010 14th International Congress of Endocrinology (Kyoto, Japan)
2010 International Congress of Obesity (ICO2010, Stockholm, Sweden)
2010 Stockholm Obesity Days (National meeting, Stockholm)
20102010 ISBRA World Congress / 13-16 September, Paris, France

Professional Affiliations and Activities:
Founder of Abunon AB (2009-). see www.abunon.com.
Patent for use of ghrelin antagonists for alcohol use disorder. Now past PCT stage and filed in many countries.
Member of the Swedish Medical Research Council’s EURYI Panel.
Member of the Editorial Board for Neuroendocrinology (1997-)
Member of the Editorial Board for the Endocrinology Domain of TheScientificWorldJOURNAL (2005-)
Member of the Physiological Society (1993-), British Neuroendocrine Group (1990-), Endocrine Society (1991-), Growth Hormone Research Society (1993-), European Neuroendocrine Society (1999-), North American Association for the study of obesity (1996-)
Referee of manuscripts for several journals notably Neuroendocrinology, J Endocrinology, J Neuroendocrinology and Endocrinology.
Coorindator of 3 EC funded projects in the 5th, 6th and 7th Framework programme.
Principal examiner for 6 PhD theses: University of Edinburgh, UK (2002), University of Cambridge (1999 and 2000) and University of London (2000, 2004) and the University of Uppsala (2010).

Prize
Fernström Prize for Young Investigators 2006. For research on the role and actions of ghrelin signalling substances. This is a prestigious national Swedish Prize for research.

Resursperson

Handledare